Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.

Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.
复制标题

靶向乳腺癌和前列腺癌中泛素化和降解的类固醇激素受体。

DOI:
10.1038/onc.2008.320
复制
发表时间:
2008-12-04
期刊:
影响因子:
8
通讯作者:
Sakamoto KM
Sakamoto KM
中科院分区:
医学1区
文献类型:
--
作者:
Rodriguez-Gonzalez A;Cyrus K;Salcius M;Kim K;Crews CM;Deshaies RJ;Sakamoto KM

文献摘要

参考文献

被引文献

相似文献

Proteolysis targeting chimeric molecules (Protacs) target proteins for destruction by exploiting the ubiquitin-dependent proteolytic system of eukaryotic cells.We designed two Protacs that contain the peptide ‘degron’ from hypoxia-inducible factor-1α, which binds to the Von –Hippel–Lindau (VHL) E3 ubiquitin ligase complex, linked to either dihydroxytestosterone that targets the androgen receptor (AR; Protac-A), or linked to estradiol (E2) that targets the estrogen receptor-α (ERα; Protac-B). We hypothesized that these Protacs would recruit hormone receptors to the VHL E3 ligase complex, resulting in the degradation of receptors, and decreased proliferation of hormone-dependent cell lines. Treatment of estrogen-dependent breast cancer cells with Protac-B induced the degradation of ERα in a proteasome-dependent manner. Protac-B inhibited the proliferation of ERα-dependent breast cancer cells by inducing G1 arrest, inhibition of retinoblastoma phosphorylation and decreasing expression of cyclin D1, progesterone receptors A and B. Protac-B treatment did not affect the proliferation of estrogen-independent breast cancer cells that lacked ERα expression. Similarly, Protac-A treatment of androgendependent prostate cancer cells induced G1 arrest but did not affect cells that do not express AR. Our results suggest that Protacs specifically inhibit the proliferation of hormone-dependent breast and prostate cancer cells through degradation of the ERα and AR, respectively.
DOI: 10.1021/ol035234c
发表时间: 2003-09-18
期刊: ORGANIC LETTERS
影响因子: 5.2
作者:
Kirschberg, TA;VanDeusen, CL;Wender, PA
通讯作者: Wender, PA
DOI: 10.1093/nar/16.2.647
发表时间: 1988-01-25
影响因子: 14.9
作者:
KLEINHITPASS, L;RYFFEL, GU;CATO, ACB
通讯作者: CATO, ACB
DOI: 10.1038/6495
发表时间: 1999-03-01
期刊: NATURE MEDICINE
影响因子: 82.9
作者:
Craft, N;Shostak, Y;Sawyers, CL
通讯作者: Sawyers, CL
DOI: 10.1210/en.2002-0092
发表时间: 2003-08-01
期刊: ENDOCRINOLOGY
影响因子: 4.8
作者:
Alarid, ET;Preisler-Mashek, MT;Solodin, NM
通讯作者: Solodin, NM
DOI: 10.1158/0008-5472.can-07-0967
发表时间: 2007-06-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Duong, Vanessa;Boulle, Nathalie;Cavailles, Vincent
通讯作者: Cavailles, Vincent